To develop
adriamycin (ADM)-encapsulated
poly(lactic-co-glycolic acid) (PLGA) nanoparticles in a porous
nano-hydroxyapatite/collagen scaffold (ADM-PLGA-NHAC). To provide novel strategies for future treatment of
osteosarcoma, the properties of the scaffold, including its in vitro extended-release properties, the inhibition effects of ADM-PLGA-NHAC on the
osteosarcoma MG63 cells, and its bone repair capacity, were investigated in vivo and in vitro. The PLGA copolymer was utilized as a
drug carrier to deliver ADM-PLGA nanoparticles (ADM-PLGA-NP). Porous nano-
hydroxyapatite and
collagen were used to materials to produce the porous
nano-hydroxyapatite/collagen scaffold (NHAC), into which the ADM-PLGA-NP was loaded. The performance of the
drug-carrying scaffold was assessed using multiple techniques, including scanning electron microscopy and in vitro extended release. The
antineoplastic activities of scaffold extracts on the human
osteosarcoma MG63 cell line were evaluated in vitro using the cell counting kit-8 (CCK8) method and live-dead cell staining. The bone repair ability of the scaffold was assessed based on the establishment of a femoral condyle defect model in rabbits. ADM-PLGA-NHAC and NHAC were implanted into the rat muscle bag for immune response experiments. A
tumor-bearing nude mice model was created, and the TUNEL and HE staining results were observed under optical microscopy to evaluate the
antineoplastic activity and toxic side effects of the scaffold. The composite scaffold demonstrated extraordinary extended-release properties, and its extracts also exhibited significant inhibition of the growth of
osteosarcoma MG63 cells. In the bone repair experiment, no significant difference was observed between ADM-PLGA-NHAC and NHAC by itself. In the immune response experiments, ADM-PLGA-NHAC exhibited remarkable biocompatibility. The in vivo antitumor experiment revealed that the implantation of ADM-PLGA-NHAC in the
tumor resulted in a improved
antineoplastic effect and fewer adverse side effects than direct
intraperitoneal injection of ADM. The ADM-PLGA-NHAC developed in this study exhibited excellent extended-release drug properties, bone repairing and
antineoplastic efficacy, which make it a promising osteoconductivity material with the capability to inhibit
osteosarcoma.